Ps Oluga Seeks Stronger Novartis Partnership For Ncds, Cancer Care
img_tag = ("The Ministry of Health is pushing for a game-changing partnership that could transform how millions of Kenyans access life-saving treatment for cancer, diabetes, and other chronic diseases that are quietly devastating families across the country.
Health Principal Secretary Mary Muthoni Oluga met with global pharmaceutical giant Novartis representatives this week, demanding stronger collaboration to tackle non-communicable diseases, cancer care, sickle cell disease, and palliative care services. The high-stakes discussions focused on making essential medications more accessible and affordable for ordinary Kenyans who currently struggle to afford treatment.
The timing couldn't be more critical. Cancer cases in Kenya have skyrocketed, with many families selling everything they own – from their small businesses to their livestock – just to afford a single round of chemotherapy. Diabetes and hypertension are no longer diseases of the wealthy; they're hitting matatu drivers, market vendors, and teachers who can barely afford their monthly medication from neighborhood pharmacies.
Sickle cell disease affects thousands of Kenyan children, particularly in counties like Homa Bay and Kisumu, where families watch helplessly as their loved ones endure painful crises without proper pain management. Many patients currently travel from remote counties to Nairobi's Kenyatta National Hospital, spending their entire savings on transport and accommodation, only to find limited treatment options.
The proposed partnership could revolutionize access to modern cancer drugs and diabetes medications that currently cost more than most Kenyans earn in several months. PS Oluga emphasized the need for innovative financing models that work with Kenya's unique healthcare landscape, including integration with NHIF and potential M-Pesa payment systems for medication adherence programs.
Novartis brings decades of experience in developing patient assistance programs across Africa, including drug donation initiatives and training programs for healthcare workers. Their expertise in oncology and rare diseases could help Kenya establish comprehensive cancer centers beyond Nairobi, bringing specialized care closer to patients in counties where a cancer diagnosis currently feels like a death sentence.
This partnership represents more than just another corporate deal – it's about whether Kenya can build a healthcare system that doesn't force families to choose between treating their sick relatives and keeping their children in school. Will this collaboration finally make world-class treatment accessible to the matatu driver battling diabetes or the teacher fighting cancer in rural Kenya?